SlideShare a Scribd company logo
ISCHEMIC HEART DISEASE
Dr Hemant k Jain
Associate Professor
Medicine,GMC Datia
 Coronary Artery Disease (CAD): >50% luminal
stenosis of any epicardial coronary arteries.
 CAD manifestations includes
◦ Stable Angina
◦ Acute Coronary Syndrome
◦ Congestive Heart Failure
◦ Sudden Cardiac Death
◦ Silent ischaemia
 ACS - USA, MI (NSTEMI, STEMI)
 USA: chest pain + ECG changes without
elevation of cardiac biomarkers
 MI: chest pain + ECG changes with
elevation of cardiac biomarkers
Cause
 Imbalance between
◦Myocardial oxygen supply
◦Demand
Diagram of the coronary arteries arising from the aorta and encircling
the heart.
 Determinants of myocardial oxygen
demand
◦ Heart rate
◦ Myocardial contractility
◦ Myocardial wall tension (stress)
◦ LVH
◦ Valve disease- AS
Determinants of myocardial oxygen supply
 Oxygen carrying capacity of blood
◦ Very severe anemia
◦ Corboxy Hb
 Coronary blood flow- luminal stenosis
◦ 50% - inability to ↑ flow to meet ↑ed MVO2
◦ 80%- blood flow at rest reduced
◦ >80%- MI
 Total occlusion in the absence of
collaterals for duration of
◦ ≤ 20 min - reversible
◦ >20 min – irreversible
Risk Factors
 Smoking
 Hypertension
 Diabetes mellitus
 Obesity
 Dyslipidemia
 Sedentary life style
 Family history of premature CAD
 Age
 Male > 45years
 Female > 55years
Clinical features…
 Chest pain
 Breathlessness
 Exercise intolerance
 Fatigue
 Palpitations
 Atypical presentations(heart failure, heart burn, nausea, vomiting,
light-headedness or loss of conciousness )
 Features of Sympathetic over-activity(anxiety,
restlessness, tachycardia, profuse perspiration, peripheral
vasoconstriction, cyanosis)
ANGINA
 Stable Angina
 Variant Angina
 Decubitus Angina
 Nocturnal Angina
 Unstable Angina
Stable Angina
 Fixed atheromatous stenosis of one or
more coronry arteries
 Typical anginal pain
◦ Retrosternal, tightness or discomfort
◦ Radiating to left(± right) shoulder/arm/
neck/jaw
◦ Brief duration, lasting <10-15 min
◦ Associated with diaphoresis, nausea, anxiety
◦ Worse on exertion
◦ Relieved by rest and nitrates
Positive Levine sign-When pt is asked to localize the pain, he/ she typically places a
hand over the sternum, sometimes with a clenched fist, to indicate a squeezing,
central, substernal discomfort
Canadian Cardiovascular Society classification
system
Class Definition
CCS
1
Angina with strenuous activity
CCS
2
Angina with moderate activity (walking
greater than two blocks)
CCS
3
Angina with mild activity (walking less
than two blocks)
CCS
4
Angina with any activity or at rest
Precipitating factors
 Emotional stress
 Exertion
 Exposure to very hot or cold
temperatures
 Eating ( Heavy meals)
 Smoking
Variant Angina (Prinzmetal Angina)
 A spasm in coronary artery
◦ Exposure to cold
◦ Emotional stress
◦ Medicines that tighten or narrow blood vessels
◦ Smoking
◦ Cocaine use
 Occurs at rest
 Not related to exertion
 Small elevations of cardiac enzymes may
occur
 Beta blockers contraindicated
 CCB / nitrate/ other vasodilators are useful
Syndrome X
 Coronary microvascular disease that affects the
heart’s smallest coronary arteries.
 Typical symptoms of angina but normal
angiogram
 May show definite signs of ischemia with
exercise testing
 Nocturnal Angina
 Angina during sleep (REM)
 Decubitus Angina
 Anginal pain in supine (recumbent) position
Physical examination
 Often normal
 Look for evidences of risk factors
Investigations
 Biochemical
◦ FBS, PPBS, HbA1c, urine r/m,
◦ Lipid profile
◦ RFT
◦ T3,T4, TSH
◦ CBC
◦ Hs-CRP
◦ CPKMB, Trop T&I
 ECG
◦ Often normal
◦ Old MI changes
◦ LVH
 Stress exercise testing
◦ Most useful noninvasive procedure for
evaluation of angina.
 Stress testing with imaging
◦ Echocardiographic imaging
◦ Myocardial perfusion imaging
◦ MR perfusion imaging
 Pharmacological stress testing
◦ Dobutamine
 Coronary arteriography
◦ Gold standard
◦ Quantify the presence and severity of
atherosclerotic lesions
◦ Assess the non-atherosclerotic causes of
ischemia(eg.-coronary anomaly, aortic
dissection, radiation vasculopathy)
TREATMENT
 Goals of treatment
◦ To prevent MI
◦ To reduce cardiac death
◦ To reduce symptoms
 Treatment modalities
◦ Medical therapy
◦ Coronary Revasularization
◦ Lifestyle modifications
◦
 Improve myocardial oxygen supply
 Reduce MVO2(myocardial volume
oxygen consumption)= SBP*HR
 Control exacerbating factors
 Limit the development of further
atherosclerotic disease
Medical therapy
Agents action
Aspirin
clopidogrel
Prevent Pletlets aggregation
and Reduce thrombus
formation
Nitrate Arteriovenous dilation
ACEIs
Beta blockers Reduce MVO2
Ranolazine Noval anti anginal agent
HMG CoA reductase
inhibitors (Statins)
Limit atherosclerotic burden
and reduce cardiac
outcomes
Coronary revascularization
 Primary coronary intervention (PCI)
 Coronary Artery Bypass Graft (CABG)
 Indications
◦ Angina refractory to medical therapy
◦ Angina with reduced LV function
◦ Severe activity limiting Angina (CCS class III-IV)
◦ Angina in the presence of LMCA(left main CA) or
severe TVD
Cardiac
catheterization
#
vessels
1,2 ≥3
STENT CABG
Unstable Angina
 Dynamic obstruction d/t plaque rupture
or erosions with superimposed
thrombosis
 more severe and lasts longer than SA,
may be as long as 30 minutes
 Not relieved by rest or nitrate
 10-20% risk of progression to acute MI
 Have a
Good life
With low cardiac risk factors And
Lots of Good days with
lots of exercise capacity

More Related Content

Similar to IHD.pptx

ANGINA.pptx
ANGINA.pptxANGINA.pptx
Reducing your Risk of Cardiovascular Disease
Reducing your Risk of Cardiovascular DiseaseReducing your Risk of Cardiovascular Disease
Reducing your Risk of Cardiovascular Disease
tbrame
 
Pathophysiology of Coronary Artery Disease
Pathophysiology of Coronary Artery DiseasePathophysiology of Coronary Artery Disease
Pathophysiology of Coronary Artery Disease
Netraranjn
 
CAD+And+ACS
CAD+And+ACSCAD+And+ACS
CAD+And+ACS
dhavalshah4424
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
dratin75
 
Coronary artery disease slide
Coronary artery disease slideCoronary artery disease slide
Coronary artery disease slide
82657885
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.ppt
Shama
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
Aparna A
 
Coronary heart disease
Coronary heart diseaseCoronary heart disease
Coronary heart disease
Ivan Luyimbazi
 
Ihd 2
Ihd 2Ihd 2
IHD and CRF by Dr akhtar Totakhail اخترمحمد طوطاخیل
IHD  and CRF by Dr akhtar Totakhail اخترمحمد طوطاخیلIHD  and CRF by Dr akhtar Totakhail اخترمحمد طوطاخیل
IHD and CRF by Dr akhtar Totakhail اخترمحمد طوطاخیل
DrAkhtarMohammadTota
 
CONTENT.pptx
CONTENT.pptxCONTENT.pptx
CONTENT.pptx
SanjayYadav20565
 
Cardiovascular Effects, Dr. C Sedacca, 4/5/14
Cardiovascular Effects, Dr. C Sedacca, 4/5/14Cardiovascular Effects, Dr. C Sedacca, 4/5/14
Cardiovascular Effects, Dr. C Sedacca, 4/5/14
upstatevet
 
CARDIOGENIC SHOCK
CARDIOGENIC SHOCKCARDIOGENIC SHOCK
CARDIOGENIC SHOCK
Mahi Yeruva
 
IHD.pptx
IHD.pptxIHD.pptx
Anaesthetic Management of a Patient with Ischaemic Heart Disease
Anaesthetic Management of a Patient with Ischaemic Heart DiseaseAnaesthetic Management of a Patient with Ischaemic Heart Disease
Anaesthetic Management of a Patient with Ischaemic Heart Disease
Zareer Tafadar
 
Acute Coronary Disease
Acute Coronary DiseaseAcute Coronary Disease
Acute Coronary Disease
BALASUBRAMANIAM IYER
 
6- ACS Dr.Nounnnnnnnnnnnnnnnnnnnnradden Al-Jaber.ppt
6- ACS Dr.Nounnnnnnnnnnnnnnnnnnnnradden Al-Jaber.ppt6- ACS Dr.Nounnnnnnnnnnnnnnnnnnnnradden Al-Jaber.ppt
6- ACS Dr.Nounnnnnnnnnnnnnnnnnnnnradden Al-Jaber.ppt
MosaHasen
 
Acute Coronary Syndrome, Myocardial Infarction.
Acute Coronary Syndrome, Myocardial Infarction.Acute Coronary Syndrome, Myocardial Infarction.
Acute Coronary Syndrome, Myocardial Infarction.
DR. VINAYAK BHOI
 
Case presentation on angina pectoris
Case presentation on angina pectorisCase presentation on angina pectoris
Case presentation on angina pectoris
Umme Habeeba A Pathan
 

Similar to IHD.pptx (20)

ANGINA.pptx
ANGINA.pptxANGINA.pptx
ANGINA.pptx
 
Reducing your Risk of Cardiovascular Disease
Reducing your Risk of Cardiovascular DiseaseReducing your Risk of Cardiovascular Disease
Reducing your Risk of Cardiovascular Disease
 
Pathophysiology of Coronary Artery Disease
Pathophysiology of Coronary Artery DiseasePathophysiology of Coronary Artery Disease
Pathophysiology of Coronary Artery Disease
 
CAD+And+ACS
CAD+And+ACSCAD+And+ACS
CAD+And+ACS
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
Coronary artery disease slide
Coronary artery disease slideCoronary artery disease slide
Coronary artery disease slide
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.ppt
 
Acute coronary syndrome
Acute coronary syndromeAcute coronary syndrome
Acute coronary syndrome
 
Coronary heart disease
Coronary heart diseaseCoronary heart disease
Coronary heart disease
 
Ihd 2
Ihd 2Ihd 2
Ihd 2
 
IHD and CRF by Dr akhtar Totakhail اخترمحمد طوطاخیل
IHD  and CRF by Dr akhtar Totakhail اخترمحمد طوطاخیلIHD  and CRF by Dr akhtar Totakhail اخترمحمد طوطاخیل
IHD and CRF by Dr akhtar Totakhail اخترمحمد طوطاخیل
 
CONTENT.pptx
CONTENT.pptxCONTENT.pptx
CONTENT.pptx
 
Cardiovascular Effects, Dr. C Sedacca, 4/5/14
Cardiovascular Effects, Dr. C Sedacca, 4/5/14Cardiovascular Effects, Dr. C Sedacca, 4/5/14
Cardiovascular Effects, Dr. C Sedacca, 4/5/14
 
CARDIOGENIC SHOCK
CARDIOGENIC SHOCKCARDIOGENIC SHOCK
CARDIOGENIC SHOCK
 
IHD.pptx
IHD.pptxIHD.pptx
IHD.pptx
 
Anaesthetic Management of a Patient with Ischaemic Heart Disease
Anaesthetic Management of a Patient with Ischaemic Heart DiseaseAnaesthetic Management of a Patient with Ischaemic Heart Disease
Anaesthetic Management of a Patient with Ischaemic Heart Disease
 
Acute Coronary Disease
Acute Coronary DiseaseAcute Coronary Disease
Acute Coronary Disease
 
6- ACS Dr.Nounnnnnnnnnnnnnnnnnnnnradden Al-Jaber.ppt
6- ACS Dr.Nounnnnnnnnnnnnnnnnnnnnradden Al-Jaber.ppt6- ACS Dr.Nounnnnnnnnnnnnnnnnnnnnradden Al-Jaber.ppt
6- ACS Dr.Nounnnnnnnnnnnnnnnnnnnnradden Al-Jaber.ppt
 
Acute Coronary Syndrome, Myocardial Infarction.
Acute Coronary Syndrome, Myocardial Infarction.Acute Coronary Syndrome, Myocardial Infarction.
Acute Coronary Syndrome, Myocardial Infarction.
 
Case presentation on angina pectoris
Case presentation on angina pectorisCase presentation on angina pectoris
Case presentation on angina pectoris
 

Recently uploaded

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
rishi2789
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
rishi2789
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Kosmoderma Academy Of Aesthetic Medicine
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
Dr. Jyothirmai Paindla
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
ZayedKhan38
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Holistified Wellness
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
taiba qazi
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
anaghabharat01
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
DRPREETHIJAMESP
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
PsychoTech Services
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
Dhayanithi C
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
NX Healthcare
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Pratik328635
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Jim Jacob Roy
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
Dr. Nikhilkumar Sakle
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
FFragrant
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
Torstein Dalen-Lorentsen
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
rishi2789
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
Health Advances
 

Recently uploaded (20)

CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 1_ANTI TB DRUGS.pdf
 
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdfCHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
CHEMOTHERAPY_RDP_CHAPTER 4_ANTI VIRAL DRUGS.pdf
 
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
 
Efficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in AyurvedaEfficacy of Avartana Sneha in Ayurveda
Efficacy of Avartana Sneha in Ayurveda
 
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathologypathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
 
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
 
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptxTests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
 
DECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principlesDECLARATION OF HELSINKI - History and principles
DECLARATION OF HELSINKI - History and principles
 
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHYMERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
MERCURY GROUP.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPromoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
 
Ketone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistryKetone bodies and metabolism-biochemistry
Ketone bodies and metabolism-biochemistry
 
Top Travel Vaccinations in Manchester
Top Travel Vaccinations in ManchesterTop Travel Vaccinations in Manchester
Top Travel Vaccinations in Manchester
 
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptxOutbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
 
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptxEar and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
 
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdfMedical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
 
Pharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and AntagonistPharmacology of 5-hydroxytryptamine and Antagonist
Pharmacology of 5-hydroxytryptamine and Antagonist
 
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
 
Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024Physical demands in sports - WCSPT Oslo 2024
Physical demands in sports - WCSPT Oslo 2024
 
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
CHEMOTHERAPY_RDP_CHAPTER 2 _LEPROSY.pdf1
 
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune DiseaseCell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
 

IHD.pptx

  • 1. ISCHEMIC HEART DISEASE Dr Hemant k Jain Associate Professor Medicine,GMC Datia
  • 2.  Coronary Artery Disease (CAD): >50% luminal stenosis of any epicardial coronary arteries.  CAD manifestations includes ◦ Stable Angina ◦ Acute Coronary Syndrome ◦ Congestive Heart Failure ◦ Sudden Cardiac Death ◦ Silent ischaemia
  • 3.  ACS - USA, MI (NSTEMI, STEMI)  USA: chest pain + ECG changes without elevation of cardiac biomarkers  MI: chest pain + ECG changes with elevation of cardiac biomarkers
  • 5. Diagram of the coronary arteries arising from the aorta and encircling the heart.
  • 6.  Determinants of myocardial oxygen demand ◦ Heart rate ◦ Myocardial contractility ◦ Myocardial wall tension (stress) ◦ LVH ◦ Valve disease- AS
  • 7. Determinants of myocardial oxygen supply  Oxygen carrying capacity of blood ◦ Very severe anemia ◦ Corboxy Hb  Coronary blood flow- luminal stenosis ◦ 50% - inability to ↑ flow to meet ↑ed MVO2 ◦ 80%- blood flow at rest reduced ◦ >80%- MI
  • 8.  Total occlusion in the absence of collaterals for duration of ◦ ≤ 20 min - reversible ◦ >20 min – irreversible
  • 9. Risk Factors  Smoking  Hypertension  Diabetes mellitus  Obesity  Dyslipidemia  Sedentary life style  Family history of premature CAD  Age  Male > 45years  Female > 55years
  • 10. Clinical features…  Chest pain  Breathlessness  Exercise intolerance  Fatigue  Palpitations  Atypical presentations(heart failure, heart burn, nausea, vomiting, light-headedness or loss of conciousness )  Features of Sympathetic over-activity(anxiety, restlessness, tachycardia, profuse perspiration, peripheral vasoconstriction, cyanosis)
  • 11. ANGINA  Stable Angina  Variant Angina  Decubitus Angina  Nocturnal Angina  Unstable Angina
  • 12. Stable Angina  Fixed atheromatous stenosis of one or more coronry arteries  Typical anginal pain ◦ Retrosternal, tightness or discomfort ◦ Radiating to left(± right) shoulder/arm/ neck/jaw ◦ Brief duration, lasting <10-15 min ◦ Associated with diaphoresis, nausea, anxiety ◦ Worse on exertion ◦ Relieved by rest and nitrates
  • 13. Positive Levine sign-When pt is asked to localize the pain, he/ she typically places a hand over the sternum, sometimes with a clenched fist, to indicate a squeezing, central, substernal discomfort
  • 14. Canadian Cardiovascular Society classification system Class Definition CCS 1 Angina with strenuous activity CCS 2 Angina with moderate activity (walking greater than two blocks) CCS 3 Angina with mild activity (walking less than two blocks) CCS 4 Angina with any activity or at rest
  • 15. Precipitating factors  Emotional stress  Exertion  Exposure to very hot or cold temperatures  Eating ( Heavy meals)  Smoking
  • 16. Variant Angina (Prinzmetal Angina)  A spasm in coronary artery ◦ Exposure to cold ◦ Emotional stress ◦ Medicines that tighten or narrow blood vessels ◦ Smoking ◦ Cocaine use  Occurs at rest  Not related to exertion  Small elevations of cardiac enzymes may occur  Beta blockers contraindicated  CCB / nitrate/ other vasodilators are useful
  • 17. Syndrome X  Coronary microvascular disease that affects the heart’s smallest coronary arteries.  Typical symptoms of angina but normal angiogram  May show definite signs of ischemia with exercise testing
  • 18.  Nocturnal Angina  Angina during sleep (REM)  Decubitus Angina  Anginal pain in supine (recumbent) position
  • 19. Physical examination  Often normal  Look for evidences of risk factors
  • 20. Investigations  Biochemical ◦ FBS, PPBS, HbA1c, urine r/m, ◦ Lipid profile ◦ RFT ◦ T3,T4, TSH ◦ CBC ◦ Hs-CRP ◦ CPKMB, Trop T&I
  • 21.  ECG ◦ Often normal ◦ Old MI changes ◦ LVH  Stress exercise testing ◦ Most useful noninvasive procedure for evaluation of angina.
  • 22.  Stress testing with imaging ◦ Echocardiographic imaging ◦ Myocardial perfusion imaging ◦ MR perfusion imaging  Pharmacological stress testing ◦ Dobutamine
  • 23.  Coronary arteriography ◦ Gold standard ◦ Quantify the presence and severity of atherosclerotic lesions ◦ Assess the non-atherosclerotic causes of ischemia(eg.-coronary anomaly, aortic dissection, radiation vasculopathy)
  • 25.  Goals of treatment ◦ To prevent MI ◦ To reduce cardiac death ◦ To reduce symptoms  Treatment modalities ◦ Medical therapy ◦ Coronary Revasularization ◦ Lifestyle modifications ◦
  • 26.  Improve myocardial oxygen supply  Reduce MVO2(myocardial volume oxygen consumption)= SBP*HR  Control exacerbating factors  Limit the development of further atherosclerotic disease
  • 27. Medical therapy Agents action Aspirin clopidogrel Prevent Pletlets aggregation and Reduce thrombus formation Nitrate Arteriovenous dilation ACEIs Beta blockers Reduce MVO2 Ranolazine Noval anti anginal agent HMG CoA reductase inhibitors (Statins) Limit atherosclerotic burden and reduce cardiac outcomes
  • 28. Coronary revascularization  Primary coronary intervention (PCI)  Coronary Artery Bypass Graft (CABG)  Indications ◦ Angina refractory to medical therapy ◦ Angina with reduced LV function ◦ Severe activity limiting Angina (CCS class III-IV) ◦ Angina in the presence of LMCA(left main CA) or severe TVD
  • 30. Unstable Angina  Dynamic obstruction d/t plaque rupture or erosions with superimposed thrombosis  more severe and lasts longer than SA, may be as long as 30 minutes  Not relieved by rest or nitrate  10-20% risk of progression to acute MI
  • 31.  Have a Good life With low cardiac risk factors And Lots of Good days with lots of exercise capacity

Editor's Notes

  1. O2 supply is given by coronary vessels Demand develops according to the work load
  2. **
  3. Ccs- to assess the severity of angina
  4. Treatment should be aimed at…
  5. MONA BASH C